Acetylon Pharmaceuticals Obtains $100,000,000 New Funding Round

  • Feed Type
  • Date
    7/30/2013
  • Company Name
    Acetylon Pharmaceuticals
  • Mailing Address
    70 Fargo Street Boston, MA 02210
  • Company Description
    Acetylon intends to pursue the clinical development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic effectiveness and tolerability versus current alternatives.
  • Website
    http://www.acetylon.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $100,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Acetylon intends to use the money for the research and testing of ACY-1215, a potential myeloma-fighting cancer drug, as well as three other cancer treatments.
  • M&A Terms
  • Venture Investor
    Celgene Corporation

By posting a comment, you agree to our terms and conditions.